HTR1A and Dyskinesia: In contrast, a recent study showed that vilazodone, which combines SSRI and 5-HT1A partial agonist properties [49,50,51], given in conjunction with L-DOPA inhibited the development and expression of L-DOPA-induced dyskinesia while leaving L-DOPA’s prokinetic effects intact, as assessed by the forepaw stepping test [52].